SCHEMBL148355

SCHEMBL148355

O=C(Nc1ccnc2ccccc12)c1cccc2c1[nH]c1ccccc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PABPC1 P11940 4/20 0.56
EIF4H Q15056 4/20 0.56
PTPN1 P18031 1/20 0.49
PTPN11 Q06124 1/20 0.49
MAPT P10636 3/20 0.47
PARP14 Q460N5 3/20 0.47
HDAC6 Q9UBN7 1/20 0.46
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
DNMT1 P26358 2/20 0.45
DNMT3A Q9Y6K1 2/20 0.45
DNMT3L Q9UJW3 1/20 0.45
JAK2 O60674 1/20 0.45
TP53 P04637 1/20 0.45
HTT P42858 1/20 0.45
KLK7 P49862 1/20 0.45
PLK4 O00444 1/20 0.44
CHEK1 O14757 1/20 0.44
PDPK1 O15530 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL148606 0.94 PABPC1 (0.65) PABPC1EIF4HMAPTHDAC6MEN1
SCHEMBL149086 0.79 MAPT (0.70) MAPTHDAC6MEN1KMT2AL3MBTL1
SCHEMBL147834 0.77 HTT (0.56) MAPTPARP14MEN1KMT2AL3MBTL1
SCHEMBL148468 0.74 ALDH1A1 (0.58) PARP14MEN1KMT2AL3MBTL1HTT
SCHEMBL7502761 0.73 MEN1 (0.65) PABPC1EIF4HMAPTMEN1KMT2A
SCHEMBL27907641 0.73 PBRM1 (0.53) MAPTPARP14MEN1KMT2AJAK2
SCHEMBL27579461 0.72 PLK4 (0.73) PABPC1EIF4HPTPN1PTPN11HDAC6
SCHEMBL27583488 0.72 PABPC1 (0.72) PABPC1EIF4HMAPTHDAC6MEN1
SCHEMBL394478 0.71 CFTR (0.61) PABPC1EIF4HMAPTHDAC6MEN1
SCHEMBL1902196 0.71 PTPN1 (0.67) PABPC1EIF4HPTPN1PTPN11HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362065-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-29 US disclosed
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
US-8084620-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2011-12-27 US disclosed
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 PABPC1 4423/4885EIF4H 2375/4885PTPN1 502/4885
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 PABPC1 4423/4885EIF4H 2375/4885PTPN1 502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.